Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor
Background: Patients with Crohn’s disease suffer from intestinal bile acid malabsorption. Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). In rats, ASBT is induced by glucocorticoids. Aims: To study whether human ASBT is activated...
Saved in:
Published in | Gut Vol. 53; no. 1; pp. 78 - 84 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group Ltd and British Society of Gastroenterology
01.01.2004
BMJ Publishing Group Ltd BMJ Publishing Group LTD Copyright 2004 by Gut |
Subjects | |
Online Access | Get full text |
ISSN | 0017-5749 1468-3288 1458-3288 |
DOI | 10.1136/gut.53.1.78 |
Cover
Summary: | Background: Patients with Crohn’s disease suffer from intestinal bile acid malabsorption. Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). In rats, ASBT is induced by glucocorticoids. Aims: To study whether human ASBT is activated by glucocorticoids and to elucidate the mechanism of regulation. Patients and methods: ASBT expression in ileal biopsies from patients with Crohn’s disease and from healthy subjects was quantified by western blot. ASBT promoter function was studied in luciferase assays and by electrophoretic mobility shift assay. Results: In 16 patients with Crohn’s disease, ASBT expression was reduced to 69 (7.5)% compared with healthy controls (mean (SEM); p = 0.01). In 10 healthy male volunteers, ASBT protein expression was increased 1.34 (0.11)-fold (mean (SEM); p<0.05) after 21 days’ intake of budesonide (9 mg/day) whereas expression of the peptide transporter 1 was unaffected. Reporter constructs of the human ASBT promoter were activated 15–20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide. Two glucocorticoid response elements in the ASBT promoter, arranged as inverted hexanucleotide repeats (IR3 elements), conferred inducibility by GR and dexamethasone in a heterologous promoter context and were shown to bind GR in mobility shift assays. Conclusions: Human ASBT is induced by glucocorticoids in vitro and in vivo. Induction of ASBT by glucocorticoids could be beneficial in patients with Crohn’s disease who exhibit reduced ASBT expression. This study identifies ASBT as a novel target of glucocorticoid controlled gene regulation in the human intestine. |
---|---|
Bibliography: | href:gutjnl-53-78.pdf ark:/67375/NVC-PFVKRNX8-8 PMID:14684580 Correspondence to: Dr G A Kullak-Ublick Division of Gastroenterology and Hepatology, and Division of Clinical Pharmacology and Toxicology, University Hospital, CH-8091 Zurich, Switzerland; gerd.kullak@usz.ch istex:32238588E0721561BBDAF5D8A59F5119F153266D local:0530078 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Correspondence to: Dr G A Kullak-Ublick Division of Gastroenterology and Hepatology, and Division of Clinical Pharmacology and Toxicology, University Hospital, CH-8091 Zurich, Switzerland; gerd.kullak@usz.ch D Jung and A C Fantin contributed equally to this work. |
ISSN: | 0017-5749 1468-3288 1458-3288 |
DOI: | 10.1136/gut.53.1.78 |